
The Federal Trade Commission is considering taking sworn testimony from Facebook, reported The Wall Street Journal. Chief Executive Mark Zuckerberg and Chief Operating Officer Sheryl Sandberg as part of its investigation into whether the social-media giant has violated US antitrust laws, according to people familiar with the matter.
Top Facebook officials are preparing for potential depositions and some are worried about the possibility, a person familiar with the matter said. However, the company now is most immediately planning for Mr. Zuckerberg’s scheduled July 27 appearance before the House Judiciary antitrust subcommittee, where he and other top tech executives are expected to be grilled by lawmakers.
The executives weren’t deposed in the FTC’s prior probe of Facebook for alleged consumer-privacy violations, a matter that resulted in a $5 billion settlement a year ago. FTC officials in announcing that agreement said they floated the possibility of deposing Mr. Zuckerberg as one way of extracting a bigger settlement from the company.
A Facebook spokesman said the company has continued to demonstrate to enforcement agencies that its “innovation provides more choices for consumers.” The spokesman added that Facebook looks forward to sharing its views about the competitive landscape alongside other technology leaders later this month at the congressional hearing.
Facebook is one of a handful of tech giants in the government’s crosshairs amid concerns they are too powerful and stifle competition.
Facebook-owned platforms, including Instagram and WhatsApp, have more than 2.5 billion users world-wide, and the company has emerged as one of the few dominant players in the US digital advertising market.
The FTC has been examining whether Facebook has engaged in unlawful monopolistic practices, including whether it had a strategy of buying up potential rivals for the purpose of heading off future competitive threats, reported the WSJ.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas